News Novo's Wegovy pill cleared for weight loss in EU The EU has approved Novo Nordisk's pill formulation of weight-loss therapy Wegovy, keeping the company a step ahead of arch rival Eli Lilly.
News UK first in Europe to clear Boehringer's IPF drug Jascayd Boehringer Ingelheim has won the first European approval for its new idiopathic pulmonary fibrosis (IPF) therapy, Jascayd, in the UK.
News Boehringer advances duo for aggressive cancers into phase 3 Boehringer Ingelheim steps up its push into oncology with phase 3 trials for pathfinder product Hernexeos and obrixtamig in hard-to-treat cancers.
Oncology ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C... At ASCO 2026, BI Global Head of Oncology Itziar Canamasas spoke with pharmaphorum about the company's ASCO data and broader oncology strategy.
News ADA: Safety data offset efficacy for survodutide New data with Zealand/Boehringer's survodutide reinforce its metabolic benefits, but a high discontinuation rate has raised concerns.
News Oral Wegovy backed by CHMP at May meeting The CHMP recommended eight new medicines and 13 line extensions at its May meeting, including Novo Nordisk's oral weight loss therapy.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.